Evidence map›Paper›PMID 30564934›Full record

ReviewSupportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer2019

Prevention of chemotherapy-induced nausea and vomiting after high-dose melphalan and stem cell transplantation: review of the evidence and suggestions.

Andrea Tendas, Francesco Marchesi, Andrea Mengarelli, Ombretta Annibali, Valeria Tomarchio, Debora Saltarelli, Anna Chierichini, Mirko Di Venanzio, Fabio Sollazzo, Monica Piedimonte and 9 more

Open access · greenAbstract readReview
PubMed Publisher
In one paragraph

Review in Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
0.9field-weighted citation impact, top 23% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 12 citations in OpenAlex.

  1. Trial
  2. Article
  3. Efficacy of intensive antiemetic therapy including olanzapine in multiple myeloma patients treated with high-dose melphalan with autologous stem cell transplantation.Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer · 2025
    Article
  4. Review
  5. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

19 authors at 5 institutions in 2 countries.

Andrea TendasHematology Division, S. Eugenio Hospital, Piazzale dell'Umanesimo 10, 00144, Rome, Italy. andrea.tendas@aslroma2.it.ORCID http://orcid.org/0000-0002-3858-1635
Francesco MarchesiHematology, Regina Elena National Cancer Institute, Rome, Italy.
Andrea MengarelliHematology, Regina Elena National Cancer Institute, Rome, Italy.
Ombretta AnnibaliHematology and Stem Cell Transplantation Unit, University Campus Bio-medico, Rome, Italy.
Valeria TomarchioHematology and Stem Cell Transplantation Unit, University Campus Bio-medico, Rome, Italy.
Debora SaltarelliHematology, San Giovanni-Addolorata Hospital, Rome, Italy.
Anna ChierichiniHematology, San Giovanni-Addolorata Hospital, Rome, Italy.
Mirko Di VenanzioHematology, San Giovanni-Addolorata Hospital, Rome, Italy.
Fabio SollazzoHematology, Sant'Andrea Hospital, Rome, Italy.
Monica PiedimonteHematology, Sant'Andrea Hospital, Rome, Italy.
Luca CupelliHematology Division, S. Eugenio Hospital, Piazzale dell'Umanesimo 10, 00144, Rome, Italy.
Antoine BrunoHematology, Rome Transplant Network, Department of Hematology, Stem Cell Transplant Unit, Tor Vergata University, Rome, Italy.
Gottardo De AngelisHematology, Rome Transplant Network, Department of Hematology, Stem Cell Transplant Unit, Tor Vergata University, Rome, Italy.
Luciano DelbonoWake Forest University School of Medicine, Winston Salem, NC, USA.
Pasquale NiscolaHematology Division, S. Eugenio Hospital, Piazzale dell'Umanesimo 10, 00144, Rome, Italy.
Alessio Pio PerrottiHematology Division, S. Eugenio Hospital, Piazzale dell'Umanesimo 10, 00144, Rome, Italy.
Paolo de FabritiisHematology Division, S. Eugenio Hospital, Piazzale dell'Umanesimo 10, 00144, Rome, Italy.
William ArceseHematology, Rome Transplant Network, Department of Hematology, Stem Cell Transplant Unit, Tor Vergata University, Rome, Italy.
Rome Transplant Network
St. Eugenio Hospital · ITAzienda Ospedaliera San Giovanni Addolorata · ITUniversità Campus Bio-Medico · ITCTO Andrea Alesini · ITWake Forest University · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

introductionHigh-dose melphalan (HDMel) is the most common conditioning chemotherapy regimen for autologous stem cell transplantation (SCT) in patients affected by multiple myeloma (MM). No consensus exists for the emetogenicity or prophylaxis of chemotherapy-induced nausea and vomiting (CINV) in this regimen.

methodsData on the incidence and efficacy/safety of CINV prophylaxis among patients affected by MM undergoing autologous SCT with the HDMel regimen was extracted from electronic databases and analyzed.

resultsEleven studies involving multiple CINV prophylaxis regimens were identified and included. No consensus on HDMel emetogenicity was reached, but most studies summarized the emetogenicity as moderate-high risk. An aprepitant-based three-drug regimen (aprepitant + serotonin receptor antagonist (5HT3RA) + dexamethasone) showed better efficacy than a two-drug regimen (5HT3RA + dexamethasone) for CINV prevention without increasing the frequency in adverse events.

conclusionsThe aprepitant-based three-drug regimen should be the regimen of choice for CINV prophylaxis for MM patients undergoing autologous SCT with HDMel conditioning.

Indexed as

AdultAntiemeticsAntineoplastic Agents, AlkylatingAprepitantDexamethasoneFemaleHematopoietic Stem Cell TransplantationHumansInduction ChemotherapyMaleMelphalanMultiple MyelomaNauseaQuality of LifeSerotonin AntagonistsTransplantation, AutologousAntiemeticsAntineoplastic Agents, AlkylatingAprepitantDexamethasoneMelphalanSerotonin AntagonistsAprepitantChemotherapy-induced nausea and vomitingHigh-dose melphalanQuality of lifeStem cell transplantation

Identifiers

PMID30564934
OpenAlexW2904748974

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.